Par Pharmaceutical to Be Bought by TPG for $1.9 Billion

Par Pharmaceutical Cos., a maker of generic drugs, agreed to be acquired for $1.9 billion by TPG Capital as the private-equity firm looks to gain from efforts to curtail health-care costs.

Par stockholders will receive $50 a share in cash, the Woodcliff Lake, New Jersey-based company said in a statement today. The offer carries a 37 percent premium over Par’s closing share price on July 13. Par rose to $50 at the close in New York, indicating that investors are expecting a higher bid.